Download the ICS Branding Pack
Non Discussion Abstract Session 36 Non Discussion Abstracts 749 Early experience of urodynamic improvement with botulinumtoxinA and mirabegron in the management of refractory neurogenic detrusor overactivity in spinal cord injury (SCI) patients.
Open Discussion Session 9 Open Discussion ePosters 1 104 Interaction with the peers improves the probability of acceptance of onabotulinum toxin A treatment in spinal cord injured (SCI) patients –an Indian experience.
Podium Short Oral Session 17 Health Services Research 301 WhatsApp as a tool to improve distance urology care and follow-up of spinal cord injury (SCI) patients in developing countries.
Podium Short Oral Session 21 Paediatrics, Pain and Neurogenic Dysfunction 454 Variability of response to the standard dose of 200 units of onabotulinum toxinA treatment in the management of neurogenic bladder after spinal cord injury: Clinical implication
Podium Short Oral Session 26 Botulinum Toxin and the Lower Urinary Tract 467 Redefining the indication to repeat onabotulinum toxin A in patients with neurogenic detrusor overactivity (NDO) after spinal cord injury (SCI).
Non Discussion Abstract Session 32 Non Discussion Abstracts 645 Improved criteria to judge the effectiveness of high dose, combination anticholnergics in the management of neurogenic incontinence after spinal cord injury (SCI).
Podium Poster Session 41 Neurophysiology and Bladder Dysfunction 643 Redefining refractory incontinence: Does ice water test (IWT) at one month after treatment correlate with adequacy of suppression of neurogenic detrusor overactivity (NDO) in the patients with neurogenic bladder after spinal cord injury.
Podium Poster Session 19 Neurourology and Paediatrics 173 Observations on the differences in response to Ice water test after treatment with Tolterodine-ER and Onabotulinum toxin A in patients with neurogenic bladder.
Non Discussion Poster Session 34 429 Urodynamic control and the ice water test at one month after the treatment predict the adequacy of response with Onabotulinum toxin A in patients with neurogenic bladder.
Non Discussion Abstract Session 31 Read by Title 751 Comparison of two types of botulinum A toxin injection treatment in patients with neurogenic detrusor overactivity: an Indian experience
Dr Dinesh Suman declared on the Sunday 16th February 2020 that they did not have any existing or known future financial relationships or affiliations to disclose (NONE).
Scientific Committee Member